What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
EPO-derived 11-mer · cytoprotective research peptide
Overview
Ara 290 (Cibinetide) is an 11-amino-acid engineered peptide derived from the helix B surface domain of erythropoietin (EPO). It exerts tissue-protective effects by activating the Innate Repair Receptor (IRR) — a heteromeric complex of the EPO receptor (EPOR) and the beta-common receptor (CD131) — without stimulating erythropoiesis. The compound was developed by Araim Pharmaceuticals and has completed multiple Phase 2 clinical trials, earning orphan drug designations across several indications: sarcoidosis-associated neuropathic pain (US, with Fast Track designation), sarcoidosis itself (US and EU), and prevention/improvement of graft survival and function in pancreatic islet transplantation (EU designation EU/3/16/1721; US designation as well). Its safety database is relatively substantial, but it remains unapproved and is for research use only. Independent verification confirms that the diabetic macular edema Phase 2 trial registered on ClinicalTrials.gov (NCT06626971, the pilot study cited in this profile) was terminated in 2017, with the official reason recorded as "expiry of study drug — no replacement available" — corroborating multiple secondary reports that the original sponsor, Araim Pharmaceuticals, ceased operations. As of 2026, no actively recruiting or ongoing trials for this compound appear on ClinicalTrials.gov. Vialdyne releases ARA 290 (Cibinetide) as a lyophilized undecapeptide (linear, n-terminal pyroglutamate) against a ≥ 99.0% HPLC main-peak specification, with a batch-specific Certificate of Analysis covering RP-HPLC purity, mass-spec identity, water content, residual solvents, and endotoxin. Sequence / identity confirmation is documented on the released lot.
Applications & buyer fit
Buyers in this category are research labs studying immune-modulation, cytokine signaling, and antimicrobial activity. The defining QC requirement is bacterial-endotoxin control: many of the downstream assays (NF-κB reporters, macrophage activation panels, neutrophil-priming readouts) are themselves activated by endotoxin contamination, so a clean LAL on the specific batch is a precondition rather than a nice-to-have. LL-37 and related cationic antimicrobial peptides additionally benefit from low-bind plasticware during dilution.
Sourced for
Buyer fit
Documentation that ships
Procurement note: A clean LAL result on the specific lot is the defining requirement, since many downstream assays are themselves activated by endotoxin.
Primary buyer fit: academic and contract research laboratories.
Specifications
Regulatory note
Research-use-only reference material; not for human or veterinary use.
Selected literature
Frequently asked questions
ARA-290 is a short linear peptide derived from helix B of erythropoietin, so its release file follows standard peptide-API practice: identity by mass spectrometry against the theoretical mass, purity by RP-HPLC to an area-percent acceptance limit, and a related-substances profile capturing synthesis-derived impurities. The certificate should also state net peptide content, counterion identity, water content, and residual solvents, with endotoxin and microbial limits for a compounding-oriented buyer. Because the molecule's value rests on selective engagement of the tissue-protective receptor complex rather than the erythropoietic receptor, correct identity confirmation is the anchor of the acceptance file.
Supplied as a lyophilized solid, ARA-290 is most stable in that state and should be kept desiccated and cold, with the sealed vial warmed to room temperature before opening to avoid condensation onto the powder. Reconstitution volume should be calculated from the net-peptide figure on the certificate rather than gross vial weight. Once in solution the peptide is less stable than the solid, so a buyer should aliquot, use promptly or freeze a single time, and avoid repeated freeze-thaw cycles. Recording diluent, concentration, and date maintains traceability to the released batch.
Related peptides
